Literature DB >> 9148653

Medicinal applications of delta-9-tetrahydrocannabinol and marijuana.

E A Voth1, R H Schwartz.   

Abstract

The use of crude marijuana for herbal medicinal applications is now being widely discussed in both the medical and lay literature. Ballot initiatives in California and Arizona have recently made crude marijuana accessible to patients under certain circumstances. As medicinal applications of pure forms of delta-9-tetrahydrocannabinol (THC) and crude marijuana are being considered, the most promising uses of any form of THC are to counteract the nausea associated with cancer chemotherapy and to stimulate appetite. We evaluated the relevant research published between 1975 and 1996 on the medical applications, physical complications, and legal precedents for the use of pure THC or crude marijuana. Our review focused on the medical use of THC derivatives for nausea associated with cancer chemotherapy, glaucoma, stimulation of appetite, and spinal cord spasticity. Despite the toxicity of THC delivered in any form, evidence supports the selective use of pure THC preparations to treat nausea associated with cancer chemotherapy and to stimulate appetite. The evidence does not support the reclassification of crude marijuana as a prescribable medicine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9148653     DOI: 10.7326/0003-4819-126-10-199705150-00008

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  25 in total

1.  Should physicians support the medical use of marijuana? No: evidence of its safety and efficacy is weak. Counterpoint.

Authors:  Eric A Voth
Journal:  West J Med       Date:  2002-03

2.  Guidelines for prescribing medical marijuana.

Authors:  E A Voth
Journal:  West J Med       Date:  2001-11

Review 3.  Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.

Authors:  M R Tramèr; D Carroll; F A Campbell; D J Reynolds; R A Moore; H J McQuay
Journal:  BMJ       Date:  2001-07-07

4.  Perinatal exposure to Δ9-tetrahydrocannabinol triggers profound defects in T cell differentiation and function in fetal and postnatal stages of life, including decreased responsiveness to HIV antigens.

Authors:  Catherine Lombard; Venkatesh L Hegde; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  J Pharmacol Exp Ther       Date:  2011-08-10       Impact factor: 4.030

5.  CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents.

Authors:  Catherine Lombard; Mitzi Nagarkatti; Prakash Nagarkatti
Journal:  Clin Immunol       Date:  2006-12-20       Impact factor: 3.969

6.  De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis.

Authors:  Teresa Gómez del Pulgar; Guillermo Velasco; Cristina Sánchez; Amador Haro; Manuel Guzmán
Journal:  Biochem J       Date:  2002-04-01       Impact factor: 3.857

7.  The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt.

Authors:  T Gómez del Pulgar ; G Velasco; M Guzmán
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

8.  Chemical stabilization of a Delta9-tetrahydrocannabinol prodrug in polymeric matrix systems produced by a hot-melt method: role of microenvironment pH.

Authors:  Manish Munjal; Mahmoud A ElSohly; Michael A Repka
Journal:  AAPS PharmSciTech       Date:  2006-09-01       Impact factor: 3.246

9.  Local administration of delta9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action.

Authors:  M C Ko; J H Woods
Journal:  Psychopharmacology (Berl)       Date:  1999-04       Impact factor: 4.530

10.  Anti-migraine effect of ∆9-tetrahydrocannabinol in the female rat.

Authors:  Ram Kandasamy; Cole T Dawson; Rebecca M Craft; Michael M Morgan
Journal:  Eur J Pharmacol       Date:  2017-10-28       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.